The clinical-stage biopharma Acelyrin has appointed Bruce C. Cozadd, co-founder and CEO of Jazz Pharmaceuticals (Nasdaq:JAZZ), to its board of directors. Cozadd co-founded Jazz Pharmaceuticals in 2003. Last year, the company brought in $3 billion in revenue. Cozadd continues to serve as the company’s chairperson and CEO. Before taking the helm of Jazz Pharmaceuticals, Cozadd…
Acelyrin raises $250M in Series B funding round
Founded in late 2020, Acelyrin has closed a $250 million Series B financing led by AyurMaya, an affiliated fund of Matrix Capital Management, Surveyor Capital and Westlake Village BioPartners. Other investors joining the funding round included Cowen Healthcare Investments, Decheng Capital, Marshall Wace, OrbiMed, RTW Investments, LP, Samsara BioCapital, Tybourne Capital Management and venBio Partners.…